Propyphenazone is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It is a derivative of phenylbutazone, a potent NSAID that has been largely replaced by newer, safer drugs. Propyphenazone is a pyrazolone derivative and is synthesized through a multi-step process involving reactions like alkylation and acylation. It acts as a cyclooxygenase (COX) inhibitor, reducing the production of prostaglandins which are involved in pain, inflammation, and fever. Propyphenazone is used to treat pain and fever, often in combination with other medications. However, its use has declined due to concerns about gastrointestinal side effects. While research on propyphenazone itself is limited, studies on its parent compound phenylbutazone have led to significant advancements in understanding the mechanisms of action of NSAIDs and the development of safer and more effective alternatives.'
```
propyphenazone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
propyphenazone : A pyrazolone derivative that is antipyrine substituted at C-4 by an isopropyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 3778 |
| CHEMBL ID | 28318 |
| CHEBI ID | 135538 |
| SCHEMBL ID | 23393 |
| MeSH ID | M0053469 |
| Synonym |
|---|
| AC-12099 |
| 4-isopropylantipyrine |
| brn 0204533 |
| isopropylphenazone |
| 3-pyrazolin-5-one, 4-isopropyl-2,3-dimethyl-1-phenyl- |
| isopropylantipyrine |
| 4-isopropyl-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one |
| ccris 6716 |
| 5-pyrazolone, 1-phenyl-2,3-dimethyl-4-isopropyl- |
| antipyrine, 4-isopropyl- |
| einecs 207-539-2 |
| 1-phenyl-2,3-dimethyl-4-isopropyl-3-pyrazolin-5-one |
| propifenazona [inn-spanish] |
| isopropylantipyrinum |
| isopropylantipyrin |
| 1-phenyl-2,3-dimethyl-4-isopropylpyrazol-5-one |
| 2,3-dimethyl-4-isopropyl-1-phenyl-3h-pyrazolin-5-one |
| propifenazone [dcit] |
| isopropyrine |
| propyphenazone [inn:ban:dcf] |
| larodon |
| propyphenazonum [inn-latin] |
| 3-pyrazolin-5-one, 2,3-dimethyl-4-isopropyl-1-phenyl- |
| propyphenazone |
| 3h-pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-4-(1-methylethyl)-2-phenyl- |
| 1,5-dimethyl-4-(1-methylethyl)-2-phenyl-1,2-dihydro-3h-pyrazol-3-one |
| CHEMDIV2_002457 |
| 479-92-5 |
| D01380 |
| yoshipyrin (tn) |
| isopropylantipyrine (jp17) |
| propyphenazone (inn) |
| NCGC00164612-01 |
| propyphenazonum |
| 1,5-dimethyl-2-phenyl-4-(propan-2-yl)-1,2-dihydro-3h-pyrazol-3-one |
| propifenazona |
| 4-isopropyl-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one |
| CHEBI:135538 , |
| 4-isopropyl-2,3-dimethyl-1-phenyl-5-pyrazolone |
| I0656 |
| CHEMBL28318 |
| yoshipyrin |
| HMS1375P15 |
| FT-0654525 |
| pxwlvjlkjgvoke-uhfffaoysa- |
| inchi=1/c14h18n2o/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10h,1-4h3 |
| 1,5-dimethyl-2-phenyl-4-propan-2-ylpyrazol-3-one |
| AKOS001725335 |
| STK766727 |
| cas-479-92-5 |
| dtxcid503529 |
| dtxsid6023529 , |
| tox21_112233 |
| MLS004773970 |
| smr001495368 |
| unii-oed8fv75py |
| oed8fv75py , |
| propifenazone |
| 5-24-01-00408 (beilstein handbook reference) |
| isopropchin |
| causyth |
| budirol |
| cibalgina |
| 4-isopropylphenazone |
| EPITOPE ID:124928 |
| isopropylantipyrine [jan] |
| propyphenazone [mi] |
| propyphenazone [mart.] |
| propyphenazone [ep monograph] |
| propyphenazone [inn] |
| propyphenazone [who-dd] |
| S5309 |
| SCHEMBL23393 |
| tox21_112233_1 |
| NCGC00164612-02 |
| 4-isopropyl-1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one |
| W-106059 |
| 4-isopropyl-1,5-dimethyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one # |
| isopropyl phenazone |
| HY-A0273 |
| CS-5533 |
| 4-isopropyl-1,5-dimethyl-2-phenyl-3-pyrazolone |
| mfcd00053368 |
| SR-01000536454-1 |
| sr-01000536454 |
| 4-isopropylantipyrine, analytical reference material |
| propyphenazone, european pharmacopoeia (ep) reference standard |
| propyphenazone, pharmaceutical secondary standard; certified reference material |
| propyphenazone 1.0 mg/ml in acetonitrile |
| propyphenazon |
| Q425111 |
| 4-isopropyl-1,5-dimethyl-2-phenyl-1h-pyrazol-3(2h)-one |
| DB13524 |
| BS-16890 |
| propyphenazone,(s) |
| CCG-266797 |
| 4-isopropylantipyrine;isopropylphenazone |
| propyphenazone (4-isopropylantipyrine) |
| D91192 |
Propyphenazone is a sensitizing agent in susceptible individuals. It can elicit IgE-mediated anaphylaxis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Propyphenazone is a sensitizing agent in susceptible individuals and can elicit IgE-mediated anaphylaxis. " | ( IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. Bohle, B; Ebner, C; Ebner, H; Ferreira, F; Grubmayr, K; Himly, M; Jahn-Schmid, B; Pittertschatscher, K, 2003) | 2 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Propyphenazone has been recrystallized from different polarity solvents by means of various non-ionic tensides (Tween 20 and 80, Brij 35 and Myrj 51) and the ionic sodium lauryl sulphate. " | ( [Effect of tensides on the dissolution rate and crystal pattern of propylphenazone]. Thomas, G; Voigt, R, 1985) | 1.71 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Controlled oral challenge with nonsteroidal anti-inflammatory drugs (NSAIDs) is the only definite way to detect safe NSAIDs in patients with NSAID-induced anaphylactoid reactions." | ( Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Conde, J; Delgado, J; Florido, JF; López-Pascual, E; Nieto, MA; Ortega, N; Quiralte, J; Sáenz de San Pedro, B, 2004) | 0.32 |
| "The SBPCOCs with highly selective COX-2 inhibitors were safe in patients with single-reactive, NSAID-induced anaphylactoid reactions, even in cases that involved pyrazole derivatives." | ( Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Conde, J; Delgado, J; Florido, JF; López-Pascual, E; Nieto, MA; Ortega, N; Quiralte, J; Sáenz de San Pedro, B, 2004) | 0.32 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Quantitative structure-pharmacokinetic relationships (QSPkR) have increasingly been used for the prediction of the pharmacokinetic properties of drug leads." | ( Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. Chen, YZ; Li, ZR; Yap, CW, 2006) | 0.33 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of the study was to investigate whether the analgesic effect of propyphenazone (PROP) was increased when it was administered in combination with caffeine (CAFF)." | ( Analgesic effects of propyphenazone in comparison to its combination with caffeine. Hummel, T; Kobal, G; Kraetsch, HG; Kussat, R; Lötsch, J, 1996) | 0.85 |
| " No significant differences between plasma levels of PROP were found when applied either alone or in combination with CAFF." | ( Analgesic effects of propyphenazone in comparison to its combination with caffeine. Hummel, T; Kobal, G; Kraetsch, HG; Kussat, R; Lötsch, J, 1996) | 0.61 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The relative bioavailability for these two types of tablets pointed out the differences, confirming the evident advantages for using the lyoc tablets in analgesic, antipyretic therapy." | ( [Formulations and bioavailability of propyphenazone in lyophilized tablets]. Antochi, S; Dumistrăcel, I; Gafiţanu, E, ) | 0.4 |
| "The examination of the bioavailability from 4 different preparations of propyphenazone suppositories on a fatty base, studied in 10 healthy volunteers, showed bioequivalence as was judged by means of the AUC-values." | ( [Availability of propylphenazone from suppositories. 2. Bioavailability]. Bornschein, M; Dietzsch, B; Gabrio, T; Grune, D; Hackenberger, F; Voigt, R, 1986) | 0.5 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Aminophenazone suppositories of an equivalent dosage led to significant higher values of plasma concentrations. On the other hand despite a relatively highly dosed one-week treatment propyphenazone did not lead to changes of the demethylation capacity of the liver in the majority of the patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| " On the other hand despite a relatively highly dosed one-week treatment propyphenazone did not lead to changes of the demethylation capacity of the liver in the majority of the patients." | ( [Effect of propyphenazone on drug biotransformation in the liver. A comparison with phenylbutazone using the aminopyrine breath test]. Clemens, M; Reinicke, C; Steiner, A; Stiller, KJ; Tanner, E; Wächter, G, 1988) | 0.9 |
| " Aminophenazone suppositories of an equivalent dosage led to significant higher values of plasma concentrations if compared with propyphenazone." | ( [Availability of propylphenazone from suppositories. 2. Bioavailability]. Bornschein, M; Dietzsch, B; Gabrio, T; Grune, D; Hackenberger, F; Voigt, R, 1986) | 0.48 |
| " A significant increase of the liberation rate of propyphenazone (re-crystallized from various media) has been realized by direct pressing of polyvinylpolypyrrolidone and Heweten 40 as well as by gelatine solution granulation, with which the last method exhibits the advantage of an increased accuracy of dosage and a decreased friability." | ( [The increase in the liberation rate of propyphenazone from preoral solid dosage forms]. Götte, M; Thomas, G; Voigt, R, 1985) | 0.79 |
| " Also, the specific parameters for oral solid dosage forms were determined." | ( Oral lyophilizate--an alternative for products with low-soluble drugs. Cojocaru, I; Drăgănoiu, S; Gafiţeanu, E, ) | 0.13 |
| " The RP-HPLC method was done for the determination of paracetamol, caffeine and propyphenazone in a multicomponent pharmaceutical dosage form." | ( Optimization of the RP-HPLC method for multicomponent analgetic drug determination. Ivanovic, D; Jancic, B; Malenovic, A; Medenica, M; Misljenovic, Dj, 2003) | 0.55 |
| " The proposed method is rapid and sensitive and, therefore, suitable for the routine control of these ingredients in multicomponent dosage forms." | ( Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. El-Dawy, MA; Elbarbry, FA; Mabrouk, MM, ) | 0.13 |
| Role | Description |
|---|---|
| non-steroidal anti-inflammatory drug | An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. |
| non-narcotic analgesic | A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. |
| peripheral nervous system drug | A drug that acts principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| pyrazolone | A member of the class of pyrazoles in which one of the carbons of the pyrazole ring is substituted by an oxo group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.0591 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 20.7201 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 2.1314 | 0.0002 | 14.3764 | 60.0339 | AID720691 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 10.5909 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 61.9315 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 10.0000 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 13.3332 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID173034 | Compound was evaluated for the measurement of Cerebral blood flow in inferior coliculus of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173176 | Compound was evaluated for the measurement of Cerebral blood flow in nucleus accumbens of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID173183 | Compound was evaluated for the measurement of Cerebral blood flow in sensorimotor cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID80631 | Percent relaxation of isolated guinea pig trachea. | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | New bronchodilators selected by molecular topology. |
| AID173014 | Compound was evaluated for the measurement of Cerebral blood flow in amygdala of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1164213 | Anti-inflammatory activity in Swiss mouse model of carrageenan-induced paw edema assessed as reduction in paw swelling at 50 mg/kg, sc dosed 30 mins before carrageenan challenge measured at 1 to 4 hrs post carrageenan challenge by mercury plethysmometry | 2014 | ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9 | Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. |
| AID173177 | Compound was evaluated for the measurement of Cerebral blood flow in nucleus ruber of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173030 | Compound was evaluated for the measurement of Cerebral blood flow in hippocampus cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173036 | Compound was evaluated for the measurement of Cerebral blood flow in lateral geniculate body of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173180 | Compound was evaluated for the measurement of Cerebral blood flow in parietal cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173028 | Compound was evaluated for the measurement of Cerebral blood flow in habenula of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173025 | Compound was evaluated for the measurement of Cerebral blood flow in frontal cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173015 | Compound was evaluated for the measurement of Cerebral blood flow in amygdala of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173193 | Compound was evaluated for the measurement of Cerebral blood flow in visual cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173020 | Compound was evaluated for the measurement of Cerebral blood flow in cerebellum of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173032 | Compound was evaluated for the measurement of Cerebral blood flow in hypothalamus of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173182 | Compound was evaluated for the measurement of Cerebral blood flow in piriform cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173018 | Compound was evaluated for the measurement of Cerebral blood flow in caudoputamen of Rats ((hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173194 | Compound was evaluated for the measurement of Cerebral blood flow in visual cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173017 | Compound was evaluated for the measurement of Cerebral blood flow in auditory cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173175 | Compound was evaluated for the measurement of Cerebral blood flow in nucleus accumbens of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173021 | Compound was evaluated for the measurement of Cerebral blood flow in cerebellum of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID173189 | Compound was evaluated for the measurement of Cerebral blood flow in superior coliculus of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173179 | Compound was evaluated for the measurement of Cerebral blood flow in parietal cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID173031 | Compound was evaluated for the measurement of Cerebral blood flow in hippocampus cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173178 | Compound was evaluated for the measurement of Cerebral blood flow in nucleus ruber of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID173026 | Compound was evaluated for the measurement of Cerebral blood flow in globus pallidus of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173024 | Compound was evaluated for the measurement of Cerebral blood flow in frontal cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173191 | Compound was evaluated for the measurement of Cerebral blood flow in thalamus of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID173192 | Compound was evaluated for the measurement of Cerebral blood flow in thalamus of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID173027 | Compound was evaluated for the measurement of Cerebral blood flow in globus pallidus of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173035 | Compound was evaluated for the measurement of Cerebral blood flow in inferior coliculus of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173019 | Compound was evaluated for the measurement of Cerebral blood flow in caudoputamen of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID173181 | Compound was evaluated for the measurement of Cerebral blood flow in piriform cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1164212 | Analgesic activity in Sprague-Dawley rat assessed as protection against acetic acid-induced abdominal constriction dosed 1 hr before acetic acid challenge measured for 20 mins post acetic acid challenge | 2014 | ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9 | Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. |
| AID173174 | Compound was evaluated for the measurement of Cerebral blood flow in medial geniculate body of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173186 | Compound was evaluated for the measurement of Cerebral blood flow in septal nucleus of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID173022 | Compound was evaluated for the measurement of Cerebral blood flow in cingulate cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173188 | Compound was evaluated for the measurement of Cerebral blood flow in substantia nigra of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173187 | Compound was evaluated for the measurement of Cerebral blood flow in substantia nigra of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173016 | Compound was evaluated for the measurement of Cerebral blood flow in auditory cortex of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173023 | Compound was evaluated for the measurement of Cerebral blood flow in cingulate cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID173184 | Compound was evaluated for the measurement of Cerebral blood flow in sensorimotor cortex of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173190 | Compound was evaluated for the measurement of Cerebral blood flow in superior coliculus of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173037 | Compound was evaluated for the measurement of Cerebral blood flow in lateral geniculate body of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID173033 | Compound was evaluated for the measurement of Cerebral blood flow in hypothalamus of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID80624 | Percent relaxation using isolated guinea pig trachea. | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | New bronchodilators selected by molecular topology. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID173173 | Compound was evaluated for the measurement of Cerebral blood flow in medial geniculate body of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173185 | Compound was evaluated for the measurement of Cerebral blood flow in septal nucleus of Rats (hypercapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| AID173029 | Compound was evaluated for the measurement of Cerebral blood flow in habenula of Rats (normocapnia) | 1985 | Journal of medicinal chemistry, Sep, Volume: 28, Issue:9 | 11C-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 54 (41.22) | 18.7374 |
| 1990's | 19 (14.50) | 18.2507 |
| 2000's | 27 (20.61) | 29.6817 |
| 2010's | 20 (15.27) | 24.3611 |
| 2020's | 11 (8.40) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (5.63%) | 5.53% |
| Reviews | 5 (3.52%) | 6.00% |
| Case Studies | 10 (7.04%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 119 (83.80%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||